News

The transaction, which will be carried out by a subsidiary of Merck, will expand the company’s immuno-oncology pipeline with the addition of Viralytics’ Cavatak (CVA21), an investigational oncolytic

Under the terms of the agreement, Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million

The objective of this Phase 1 is to determine safety, bio-distribution, and preliminary effectiveness of AlphaMedix in patients with somatostatin receptor positive neuroendocrine tumors (NETs). Orano Med’s CEO

The approval of the company’s New Drug Application (NDA) was granted under the US President's Emergency Plan for AIDS Relief (PEPFAR). Following the approval, Mylan said that it

SECURE study is a prospective, multi-center, randomized and double-blind placebo-controlled trial designed to assess patients with moderate to severe ulcerative colitis. SB012 is an enema formulation of hgd40,

The Phase II trial (BGBC007) follows a two-stage design: it is an open label, multi-centre study of bemcentinib in combination with KEYTRUDA in patients with previously treated, locally

As a result of the Acquisition, DanDrit owns a perpetual, fully paid up, royalty free, sublicensable, exclusive, license to new technology platforms for the treatment of HIV, including

The improvement was seen 12 weeks after treatment with Taltz injection, in comparison to placebo, said Lilly. The company said that 92% of patients treated with Taltz had

Cosentyx is a fully human interleukin-17A (IL-17A) inhibitor, which showed speedy and sustained long term efficacy in treating patients with moderate-to-severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondilytis